Immune cells from your own tumor could fight lung cancer
NCT ID NCT06473961
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a personalized treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard treatments. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then infused back into the patient. The study will enroll 20 participants to check safety and whether the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GC101 TIL (tumor infiltrating lymphocytes)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced non-small cell lung cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early Phase Ib trial with only 20 participants, so results are preliminary. The treatment involves a complex process and may cause side effects; it is not yet proven to work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.